摘要
目的:探讨糖尿病肾病及糖尿病视网膜病变抗凝治疗时,如何在二者之间寻求平衡,既达到抗凝的作用,又能够不加重视网膜小动脉出血。方法:糖尿病肾病患者随机分成4组,实验组1给予低分子肝素(法安明)3000u QDIH;实验组2给予法安明5000u QDIH;实验组3给予法安明7000u QDIH;对照组给予生理盐水作为安慰剂。比较血APTT,尿蛋白定量,肾功与直接眼底镜。结果:实验组1、实验组2与实验组3在治疗后,尿量增加显著,肾功有所恢复,呈剂量依赖关系,在APTT明显延长的情况下,无患者出现视网膜病变进行性加重。收缩血压变化不明显,尿蛋白未见明显减少。结论:在处于较早阶段的糖尿病肾病合并视网膜病变患者中,使用低分子肝素抗凝治疗是安全有效的,即使剂量较大,疗程稍长,也不会加重DR。
Objective：To find balance in anticoagulation therapy of LMWH among diabetic nephropathy complicated with diabetic retinopathy.Methods：Administrate different dose of LMWH respectively to four groups of patients suffering diabetic nephropathy complicated with diabetic retinopathy,then look up the change in APTT,proteinuria,renal function and retina vessel.Results：After administration of LMWH,urine volume and renal function restore to some extent which shows dose-depended effect in the test group 1,2 and 3,but proteinuria and blood pressure doesn＇t show this change.No diabetic retinopathy get worse since the APTT turn longer.Conclusion：It＇s safe to apply LMWH in diabetic nephropathy complicated with diabetic retinopathy in early stage even with large dose.
出处
《医学信息（中旬刊）》
2010年第10期2664-2665,共2页
Medical Information Operations Sciences Fascicule
